October 21, 2019 Bio/Pharma/CRO Environ, Ag./Food & Bev Lab Top-10 M&A, Partnerships

Danaher Reaches Agreement To Sell Certain Businesses To Sartorius AG As Part Of The GE Biopharma Acquisition Regulatory Process

Danaher Reaches Agreement To Sell Certain Businesses To Sartorius AG As Part Of The GE Biopharma Acquisition Regulatory Process WASHINGTON, Oct. 21, 2019 /PRNewswire/ — Danaher Corporation (NYSE: DHR) today announced that it has signed an agreement to sell its label-free biomolecular characterization, chromatography hardware and resins, and microcarriers and particle validation standards businesses to... Read more

October 18, 2019 Acad, Gov/Utilities Bio/Pharma/CRO

Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications

Basel, 18 October 2019 Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at... Read more

October 14, 2019 Bio/Pharma/CRO Molecular Spectroscopy Product Launch

New Handheld X-Ray Fluorescence Analyzer for Pharmaceutical Manufacturers Identifies Ionic Salt Raw Material in Seconds

New Handheld X-Ray Fluorescence Analyzer for Pharmaceutical Manufacturers Identifies Ionic Salt Raw Material in Seconds Thermo Scientific IonicX analyzer provides fast verification of ionic salts in the warehouse, saving time and money spent on lab-based wet chemistry or benchtop NIR testing TEWKSBURY, Mass., Oct. 14, 2019 /PRNewswire/ — Pharmaceutical and biopharmaceutical manufacturers can now verify... Read more

October 14, 2019 Bio/Pharma/CRO PR/Corporate

Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris

Basel, 14 October 2019 Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris 40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of patients on mycophenolate mofetil Study... Read more

October 7, 2019 Bio/Pharma/CRO M&A, Partnerships PR/Corporate

vertX Bioprocess Conference Convenes Biotech and Biopharma Leaders to Accelerate Industry Collaboration

vertX Bioprocess Conference Convenes Biotech and Biopharma Leaders to Accelerate Industry Collaboration Thermo Fisher Scientific’s forum focuses on strategies to expedite biotherapeutic development and commercialization LOGAN, Utah, Oct. 7, 2019 /PRNewswire/ — To discuss the future strategies of biologics development and commercialization, Thermo Fisher Scientific hosted the inaugural vertX Bioprocess Conference on Thursday, September 26... Read more

October 1, 2019 Bio/Pharma/CRO Lab Top-10 M&A, Partnerships

Thermo Fisher Scientific Enhances Leading Pharma Services Offering by Expanding API Manufacturing Capabilities

Thermo Fisher Scientific Enhances Leading Pharma Services Offering by Expanding API Manufacturing Capabilities Expansion follows the Completion of the Acquisition of GSK Manufacturing Site in Cork, Ireland CORK, Ireland, October 1, 2019 – Thermo Fisher Scientific, the world leader in serving science, announced the expansion of its API manufacturing capabilities following the completion of its... Read more

September 30, 2019 Bio/Pharma/CRO PR/Corporate

Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer

Basel, 30 September 2019 Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced bladder cancer Tecentriq combination reduced the risk of disease worsening... Read more

September 30, 2019 Bio/Pharma/CRO Informatics & Software M&A, Partnerships Mass Spectrometry

SCIEX and Protein Metrics Join Forces to Meet Biopharmaceutical Customers’ AI and Automation-driven Data Requirements

Integration to empower fast data processing from all SCIEX high resolution accurate mass platforms as digital transformation of life sciences industry and push towards Precision Medicine continues to drive demand for data September 30, 2019 Framingham, MA — SCIEX a global leader in life science analytical technologies, has announced an extended partnership with Protein Metrics Inc., a premier... Read more

September 27, 2019 Atomic Spectroscopy Bio/Pharma/CRO PR/Corporate

Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma

Basel, 27 September 2019 Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination... Read more